The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239300 | PMC |
| http://dx.doi.org/10.1155/2023/7061783 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Jessner Lymphocytic Infiltrate in Anti-HMGCR Myopathy.
JAMA Dermatol
December 2024
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Statin-Induced Necrotizing Autoimmune Myopathy: Diagnosis and Treatment Approach.
JCEM Case Rep
December 2024
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
The widespread use of statins for cardiovascular diseases has unveiled a new subset of inflammatory myopathy, immune-mediated necrotizing myopathy (IMNM). We describe below an unusual case of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. A 64-year-old male individual with type 2 diabetes, hyperlipidemia, and coronary artery disease presented with progressive proximal muscle weakness and pain for 3 months.
View Article and Find Full Text PDF[Not Available].
Ugeskr Laeger
October 2024
Afdeling for Hjertesygdomme, Sygehus Sønderjylland, Aabenraa.
Statin-induced immune-mediated necrotising myopathy (IMNM) is a rare complication associated with statin use. IMNM is classified as one of the inflammatory myopathies characterised by myalgia and elevated serum creatine kinase (CK) levels. In this case report, we present a 58-year-old woman who developed IMNM secondary to atorvastatin use.
View Article and Find Full Text PDFA Case of Statin-Induced Necrotizing Autoimmune Myopathy.
Cureus
October 2024
Internal Medicine, Jefferson Einstein Montgomery Hospital, East Norriton, USA.
Statins, commonly used for hyperlipidemia and more importantly having proven efficacy in lowering cardiovascular risk, are a very popular class of medications. Side effects are usually mild, and the class as a whole is generally well-tolerated by patients. However, one rare and more serious side effect is statin-induced autoimmune necrotizing myopathy.
View Article and Find Full Text PDFPrecise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.
Ann Rheum Dis
October 2024
Division of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Article Synopsis
- Anti-HMGCR-positive immune-mediated necrotising myopathy (IMNM) is linked to IgG autoantibodies against HMGCR and specific HLA-DR alleles, but HMGCR-specific CD4T-cells had not been previously identified in affected patients.
- This study demonstrated that patients with anti-HMGCR+IMNM show heightened CD4T-cell responses to HMGCR compared to those with dermatomyositis, with a significant correlation between these responses and the levels of anti-HMGCR antibodies.
- The presence of distinct HMGCR-reactive CD4T-cells in both blood and muscle tissues highlights their potential role in the disease's development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!